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A 65-year-old man was transferred from the Department of Vascular Surgery to
Nephrology because of cardiac arrest during hemodialysis. He underwent incision
and drainage for treatment of a buttock abscess. Nafamostat mesilate was used as an
anticoagulant for hemodialysis to address bleeding from the incision and drainage
site. Sudden cardiac arrest occurred after 15 minutes of dialysis. The patient was
treated in the intensive care unit for 5 days. Continuous veno-venous hemodiaﬁl-
tration was started without any anticoagulant in the intensive care unit. Conven-
tional hemodialysis was reinitiated, and nafamostat mesilate was used again
because of a small amount of continued bleeding. Ten minutes after hemodialysis,
the patient complained of anaphylactic signs and symptoms such as dyspnea, hy-
potension, and facial swelling. Epinephrine, dexamethasone, and pheniramin were
injected under the suspicion of anaphylactic shock, and the patient recovered. Total
immunoglobulin E titer was high, and skin prick test revealed weak positivity for
nafamostat mesilate. We ﬁrst report a case of anaphylactic shock caused by nafa-
mostat mesilate in Korea.
Copyright © 2015. The Korean Society of Nephrology. Published by Elsevier. This is
an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Generally, heparin is used to control circuit coagulation
during hemodialysis; however, it does affect the systemic blood
coagulation. For patients at high risk of bleeding, alternative
modalities, such as saline ﬂushes, regional citrate anti-
coagulation, prostacyclin, danaparoid, argatroban (direct
thrombin inhibitor), and lepirudin (recombinant hirudin), are
available [1]. Nafamostat mesilate is a serine protease-inhibitor
discovered by Fujii and Hitomi [2]. It has been studied for its
anticoagulant effect and used clinically in hemodialysis since
1989 [3].y, Department of Internal
esagwan-gil, Yongsan-gu,
.
ty of Nephrology. Published b
/4.0/).Nafamostat mesilate inhibits various enzyme systems, such
as coagulation and ﬁbrinolytic systems (thrombin, Xa, and XIIa),
the kallikreinekinin system, the complement system, and
pancreatic proteases. Because it is not absorbed by the anion
exchange resin, it does not affect bone and lipid metabolism [4].
It has a biological half-life of 8minutes or less, and approximately
40% of the molecule is dialyzed through the dialyzer [5]. In
addition, its anticoagulant effect is strictly limited to the extra-
corporeal circuit [5]. Because of the characteristics described
previously, it has been used in patients who are at high risk of
bleeding and those with heparin-induced thrombocytopenia.
However, several allergic reactions caused by nafamostat
mesilate have been reported in Japan. Most allergic reactions
reported that there were mild symptoms, such as abdominal
pain, nausea, vomiting, anorexia, myalgia, and arthralgia. More
serious symptoms such as severe hypotension and dyspnea,
however, have also been reported in several cases. There havey Elsevier. This is an open access article under the CC BY-NC-ND license
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nafamostat mesilate in Korea. Therefore, we would like to pre-
sent a case of anaphylactic shock caused by nafamostat mesilate.
Case report
A 65-year-old man was admitted to this hospital in March
2015 to establish new vascular access for dialysis. He was
diagnosed with hypertension and diabetes in 2004 and un-
derwent lower anterior resection for rectal cancer followed by
radiotherapy in the same year. He started maintenance hemo-
dialysis due to diabetic nephropathy in 2010. He was dialyzed
through a permanent catheter placed in the right jugular vein
at the time of admission. The Polyﬂux 14L (Poly-
arylethersulfone, Polyvinylpyrrolidone, Polyamide blend,
Steam sterilized; Gambro, Lund, Sweden) was used as a dia-
lyzer, and heparin was applied as an anticoagulant. He under-
went incision and drainage for treatment of a buttock abscess
after having received dialysis 4 times. After the second dialysis
after the operation, nafamostat mesilate was used because of
bleeding from the incision and drainage site. After initiating
dialysis with nafamostat mesilate, the patient complained of
bilateral eye congestion and buttock pain; sudden cardiac ar-
rest occurred after 15 minutes of dialysis. Spontaneous circu-
lation was restored after 7 minutes of cardiac massage.
Laboratory results at that time were as follows: white blood
cells 27.5  103/mL (eosinophil 0.1%), hemoglobin 9.9 g/dL, he-
matocrit 30.5%, platelets 296  103/mL, activated partial
thromboplastin time 118.3 seconds, prothrombin time 13.2
seconds (international normalized ratio 1.26), serum creatinine
2.58 mg/dL, blood urea nitrogen 26.8 mg/dL, aspartate trans-
aminase 35 U/L, alanine transaminase 20 U/L, total protein 4.8
g/dL, albumin 1.9 g/dL, Na 131 mmol/L, K 3.3 mmol/L, Cl 100
mmol/L, total CO2 15 mmol/L, Ca 7.1 mg/dL, phosphate 2.9 mg/
dL, glucose 297mg/dL, C-reactive protein 4.77mg/dL, and lactic
dehydrogenase level of 317 IU/L (normal range, 100e450 IU/L).
Arterial blood gas showed pH 7.263, pCO2 48.6 mmHg, pO2
153.1 mmHg, HCO3 21.5 mmol/L, and O2 saturation 98.7%.
Echocardiography results were as follows: normal left ven-
tricular systolic function, no regional wall motion abnormality,
left ventricular hypertrophy, and relaxation abnormality.
The patient recovered consciousness after return of spon-
taneous circulation, but hypotension persisted. Norepinephrine
was continuously infused for 2 days tomaintain blood pressure,
and continuous veno-venous hemodiaﬁltration was started
without any anticoagulant because of constant bleeding from
the site of the drained abscess on the buttock area. The patient
was treated in the intensive care unit for 5 days, and there were
no other complications during continuous veno-venous
hemodiaﬁltration.
Conventional hemodialysis was reinitiated, and nafamostat
mesilate was used again because of a small amount of
continued bleeding on the buttock area. Ten minutes after he-
modialysis, the patient complained of a sensation of heat on the
buttock area, dyspnea, facial swelling, and congestion of both
eyes. Blood pressure was 110/60 mmHg just before hemodial-
ysis, but soon was unmeasurable, with only a weak pulse felt
over the femoral artery. Intramuscular epinephrine, intrave-
nous dexamethasone, and intravenous pheniramin were
injected under the suspicion of anaphylactic shock, and the
blood pressure recovered to 80/50 mmHg. Predialysis labora-
tory results were as follows: white blood cells 7.4  103/mL(eosinophil 9.6%), hemoglobin 10.0 g/dL, hematocrit 30.1%, and
platelet count 65  103/mL. Serum creatinine was 2.18 mg/dL,
blood urea nitrogen 23.0 mg/dL, aspartate transaminase 24 U/L,
alanine transaminase 8 U/L, total protein 5.3 g/dL, albumin 2.3
g/dL, Na 137 mmol/L, K 4.3 mmol/L, Cl 102 mmol/L, total CO2 23
mmol/L, and lactic dehydrogenase 206 IU/L.
Nafamostat mesilate was a suspected cause of the anaphy-
lactic shock. A skin prick test and total immunoglobulin E (IgE)
test were performed for evaluation of nafamostat mesilate al-
lergy.We could not perform speciﬁc IgE testing because the test
equipment was not available. Nafamostat mesilate allergy was
ultimately diagnosed based on a weak positive result on skin
prick test and elevation of total IgE. There were no additional
events in subsequent hemodialysis runs without nafamostat
mesilate. He underwent surgery to establish new vascular ac-
cess and was subsequently discharged.
Discussion
Nafamostat mesilate is a serine protease inhibitor that in-
hibits various enzyme systems, such as coagulation and ﬁbri-
nolytic systems (thrombin, Xa, and XIIa), the kallikreinekinin
system, the complement system, and pancreatic proteases.
Nafamostat mesilate has 3 advantageous features compared to
heparin. First, it does not affect systemic coagulation; second, it
inhibits the complement system; and third, it has no lipolytic
activity [4]. In addition, Chika et al [6] reported that nafamostat
mesilate inhibited plasma bradykinin elevation and can pre-
vent anaphylactic shock, which is induced by low-density li-
poprotein apheresis with heparin. Therefore, the use of
nafamostat mesilate has advantages over heparin if the pa-
tients are at high risk of bleeding. However, there have been
several cases of allergic reactions to nafamostat mesilate.
Yamazato et al [3] reported a patient who complained of severe
abdominal pain and throat irritation during the sixth hemodi-
alysis run using nafamostat mesilate; in that case, the drug
lymphocyte stimulation test and speciﬁc IgE were positive.
Akizawa [4] reported that 3 of 66 patients complained of
anorexia, general lassitude, slight myalgia, and arthralgia dur-
ing hemodialysis using nafamostat mesilate, and symptoms
disappeared after the end of dialysis. Maruyama et al [5]
described the ﬁrst case of an anaphylactoid reaction caused
by nafamostat mesilate. Their patient complained of nausea,
vomiting, sweating, chest discomfort, and abdominal pain fol-
lowed by shock. The drug lymphocyte stimulation test was
positive for nafamostat mesilate, whereas speciﬁc IgE was
negative in the reported case. Higuchi et al [7] reported a pa-
tient with hypotension that occurred during his ninth hemo-
dialysis run using nafamostat mesilate. In that case, the drug
lymphocyte stimulation test for nafamostat mesilate was pos-
itive, but speciﬁc IgEwas negative. Shunsuke et al [8] reported a
case of acquired allergic reaction to nafamostat mesilate during
long-term maintenance of hemodialysis.
Similar to the case of Shunsuke et al [8], our patient had a
historyofnafamostatmesilate exposure at least 1 year before, but
there were no previous adverse events. Cardiac arrest occurred
during the ﬁrst hemodialysis with nafamostat mesilate at our
hospital. Unfortunately, the mechanism of nafamostat mesilate
anaphylaxis remains unclear, as in the previously reported cases.
Nagase et al [9] reported that the speciﬁc IgE antibody to nafa-
mostatmesilate has high sensitivity to allergic reaction.Wecould
not conclude the exact mechanism of nafamostat mesilate
Kim et al / Nafamostat mesilateeinduced anaphylactic shock 189anaphylaxis because speciﬁc IgE was not tested in our case.
Nevertheless, elevated serum total IgE andweakpositivity to skin
prick test indirectly suggested that themainmechanismmightbe
related to IgE-mediated allergic reaction.
In conclusion, various etiologies, such as cardiovascular
disease, sepsis, air embolism, and membrane reaction, must be
evaluated as potential causes of cardiac arrest during dialysis,
and anaphylactic shock due to drug allergy should also be
considered. Clinical suspicion is very important in diagnosing
nafamostat mesilate allergy. If patients complain of unusual
symptoms repeatedly during dialysis using nafamostat mesi-
late, it is important to check their allergy histories and to
perform a skin prick test for nafamostat mesilate. Skin prick test
is very useful because it is easy to perform and it provides re-
sults within few minutes. If an allergic reaction occurs, typical
treatment for anaphylaxis including hydration, epinephrine,
antihistamine, and steroid injection should be performed.
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